EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Genome‐Wide DNA Methylation Identifies Potential Disease‐Specific Biomarkers and Pathophysiologic Mechanisms in Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Celiac Disease

Swapna Mahurkar-Joshi, Mike Thompson, Elizza Villarruel, James D Lewis, Lisa D Lin, Mary Farid, Hamed Nayeb-Hashemi, Tina Storage, Guy A Weiss, Berkeley N Limketkai, Jenny S Sauk, Emeran A Mayer and 1 more

Neurogastroenterology & Motility · 2025-02 · 37 (2)

DOI: 10.1111/nmo.14980 ↗

At a glance

Journal article in Neurogastroenterology & Motility, published online on 2024-12-13. Written by Swapna Mahurkar-Joshi and 12 co-authors. Institution: G. Oppenheimer Center for the Neurobiology of Stress and Resilience, Los Angeles, California, USA. Major MEDLINE topics: DNA Methylation, Irritable Bowel Syndrome, Celiac Disease, Inflammatory Bowel Diseases. Cited 7 times so far (Crossref); 81 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS, Technology Development Group, UCLA, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and celiac disease (CeD) present with similar gastrointestinal (GI) symptoms. DNA methylation‐based biomarkers have not been investigated as diagnostic biomarkers to classify these disorders. We aimed to study DNA methylation profiles of IBS, IBD, CeD, and healthy controls (HC), develop machine learning‐based classifiers, and identify associated gene ontology (GO) terms.

Methods

Genome‐wide DNA methylation of peripheral blood mononuclear cells from 315 patients with IBS, IBD, CeD, and HC was measured using Illumina's 450K or EPIC arrays. A methylation dataset on 304 IBD and HC samples was used for external validation. Differential methylation was measured using general linear models. Classifiers were developed using penalized generalized linear models using double cross‐validation controlling for confounders. Functional enrichment was assessed using GO.

Results

Three hundred and fifteen participants (148 IBS, 47 IBD, 34 CeD, and 86 HC) had DNA methylation data. IBS‐IBD and IBD‐CeD showed the highest number of differentially methylated CpG sites followed by IBD‐HC, CeD‐HC, and IBS‐HC. IBS‐associated genes were enriched in cell adhesion and neuronal pathways, while IBD‐ and CeD‐associated markers were enriched in inflammation and MHC class II pathways, respectively ( p < 0.05). Classification performances assessed using area under the receiver operating characteristic curves (AUC) for IBS‐IBD, IBS‐CeD, and IBD‐CeD were 0.80 (95% CI = 0.7–0.87, p = 6.75E‐10), 0.78 (95% CI = 0.68–0.86, p = 4.57E‐10), and 0.73 (95% CI = 0.62–0.83, p = 0.03), respectively. The performance of IBD‐HC was successfully validated using external data (AUC = 0.74 [95% CI = 68–0.80, p < 0.001]).

Conclusions

Blood‐based DNA methylation biomarkers can potentially distinguish chronic GI disorders that present with similar symptoms. GO suggested functional significance of the classifiers in disease‐specific pathology.

Subjects

MeSH terms (MEDLINE)

DNA MethylationIrritable Bowel SyndromeCeliac DiseaseInflammatory Bowel DiseasesHumansMaleFemaleAdultBiomarkersMiddle AgedGenome-Wide Association StudyMachine Learning

Author keywords

Celiac DiseaseDNA Methylation‐Based BiomarkersInflammatory Bowel DiseaseIrritable Bowel SyndromeMachine Learning

Substances

Biomarkers

Authors and institutions

  • G. Oppenheimer Center for the Neurobiology of Stress and Resilience, Los Angeles, California, USA.
  • Vatche and Tamar Manoukian Division of Digestive Diseases, Los Angeles, California, USA.
  • David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Systems Biology, Centre for Genomic Regulation, Barcelona, Spain.
  • Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • UCLA Celiac Disease Program, Los Angeles, California, USA.

ORCID profiles: Lin Chang

Funding

  • NIDDK NIH HHS
  • Technology Development Group, UCLA
  • NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health

Cite

APA

Mahurkar-Joshi, S., Thompson, M., Villarruel, E., Lewis, J. D., Lin, L. D., Farid, M., Nayeb-Hashemi, H., Storage, T., Weiss, G. A., Limketkai, B. N., Sauk, J. S., Mayer, E. A., & Chang, L. (2025). Genome‐Wide DNA Methylation Identifies Potential Disease‐Specific Biomarkers and Pathophysiologic Mechanisms in Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Celiac Disease. Neurogastroenterology & Motility, 37(2). https://doi.org/10.1111/nmo.14980

Vancouver

Mahurkar-Joshi S, Thompson M, Villarruel E, Lewis JD, Lin LD, Farid M, et al. Genome‐Wide DNA Methylation Identifies Potential Disease‐Specific Biomarkers and Pathophysiologic Mechanisms in Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Celiac Disease. Neurogastroenterology & Motility. 2025;37(2). doi:10.1111/nmo.14980

BibTeX
@article{MahurkarJoshi2025,
  author = {Mahurkar-Joshi, Swapna and Thompson, Mike and Villarruel, Elizza and Lewis, James D and Lin, Lisa D and Farid, Mary and Nayeb-Hashemi, Hamed and Storage, Tina and Weiss, Guy A and Limketkai, Berkeley N and Sauk, Jenny S and Mayer, Emeran A and Chang, Lin},
  title = {Genome‐Wide DNA Methylation Identifies Potential Disease‐Specific Biomarkers and Pathophysiologic Mechanisms in Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Celiac Disease},
  journal = {Neurogastroenterology & Motility},
  year = {2025},
  volume = {37},
  number = {2},
  doi = {10.1111/nmo.14980}
}
Start for free →